+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Glaucoma Treatment Market by Treatment Type (Laser Treatment, Medical Treatment, Surgical Treatment), Drug Class (Alpha Agonists, Beta Blockers, Carbonic Anhydrase Inhibitors), Route Of Administration, Product Type, Distribution Channel, End Use - Global Forecast 2025-2030- Product Image
Glaucoma Treatment Market by Treatment Type (Laser Treatment, Medical Treatment, Surgical Treatment), Drug Class (Alpha Agonists, Beta Blockers, Carbonic Anhydrase Inhibitors), Route Of Administration, Product Type, Distribution Channel, End Use - Global Forecast 2025-2030- Product Image
Sale

Glaucoma Treatment Market by Treatment Type (Laser Treatment, Medical Treatment, Surgical Treatment), Drug Class (Alpha Agonists, Beta Blockers, Carbonic Anhydrase Inhibitors), Route Of Administration, Product Type, Distribution Channel, End Use - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 191 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5305564
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Glaucoma Treatment Market grew from USD 7.31 billion in 2024 to USD 7.99 billion in 2025. It is expected to continue growing at a CAGR of 9.03%, reaching USD 12.28 billion by 2030.

Unveiling the Imperatives of Modern Glaucoma Treatment Approaches to Defeat Disease Progression Amidst a Rapidly Evolving Ophthalmic Therapeutic Landscape

Glaucoma persists as one of the most challenging ophthalmic diseases, characterized by progressive optic neuropathy that often culminates in irreversible vision loss. As life expectancy rises globally, the prevalence of glaucoma intensifies, placing mounting pressure on healthcare systems to advance early detection, optimize therapeutic efficacy, and minimize patient burden. The complexity of intraocular pressure modulation, neuroprotection, and individualized patient profiles necessitates a holistic understanding of evolving clinical protocols and technological innovations.

Against this backdrop, clinicians, researchers, and industry leaders are converging to pioneer new treatment paradigms that transcend traditional pharmacological management. Breakthroughs in surgical and laser interventions offer promising pathways to achieve sustained intraocular pressure control, while emerging drug classes are expanding the armamentarium for neuroprotective strategies. This introduction lays the foundation for a detailed exploration of transformative shifts, regulatory influences, segmentation dynamics, regional disparities, and competitive landscapes that collectively shape the future of glaucoma treatment.

Disruptive Technological Breakthroughs and Personalized Therapeutics Recalibrating Glaucoma Management and Diagnostic Protocols Worldwide

The landscape of glaucoma management is experiencing a wave of transformative shifts driven by technological innovation and personalized medicine. Novel minimally invasive glaucoma surgery platforms are redefining safety and efficacy benchmarks, enabling earlier intervention and faster patient recovery. At the same time, sustained-release drug delivery systems are breaking ground by reducing dosing frequency and enhancing adherence, with biodegradable implants and punctal plugs poised to become standard adjuncts to topical therapies.

Parallel advances in diagnostic modalities, including high-resolution optical coherence tomography and artificial intelligence-driven image analysis, are empowering clinicians to detect subtle structural changes sooner and tailor treatment regimens with unprecedented precision. The integration of teleophthalmology and remote monitoring tools is further democratizing access, particularly in underserved regions where specialist care may be limited. Together, these disruptive technologies and patient-centric innovations are recalibrating long-established protocols, challenging stakeholders to adopt agile strategies that harness data insights, streamline care pathways, and deliver measurable improvements in long-term visual outcomes.

Assessing Escalating United States Tariffs in 2025 and Their Far-Reaching Implications on Glaucoma Treatment Supply Chains and Market Dynamics

Escalating United States tariffs scheduled for 2025 on ophthalmic devices and pharmaceutical components are poised to reshape cost structures across the glaucoma treatment continuum. Manufacturers reliant on imported active ingredients for carbonic anhydrase inhibitors, prostaglandin analogs, and advanced device materials will face increased input costs, with downstream implications for pricing strategies and reimbursement negotiations. In response, several leading suppliers are exploring alternative sourcing agreements and nearshoring partnerships to mitigate exposure to adverse tariff impacts.

Beyond raw materials, the import duties on specialized laser equipment and minimally invasive glaucoma surgery implants are prompting healthcare providers to reassess capital procurement plans and balance investment in novel therapies with budgetary constraints. Transitional agreements and tariff exclusions may provide temporary relief, but long-term resilience will depend on supply chain diversification, regional manufacturing hubs, and collaborative value-based contracting with payers. The intersection of trade policy and ophthalmic innovation underscores the strategic importance of proactive risk management to sustain access to critical treatments.

Revealing Core Insights from Six Critical Segmentation Dimensions That Define the Heterogeneous Glaucoma Treatment Landscape

An in-depth examination of key segmentation dimensions reveals the heterogeneous nature of the glaucoma treatment ecosystem. When considering treatment type, stakeholders engage across laser modalities-ranging from argon laser trabeculoplasty to endocyclophotocoagulation and selective laser trabeculoplasty-alongside medical therapies and surgical interventions, which encompass drainage device implantation, trabeculectomy, and minimally invasive glaucoma surgery platforms such as Hydrus, iStent, and Xen Gel Stent. Examining drug class highlights a spectrum from established prostaglandin analogs, beta blockers, and carbonic anhydrase inhibitors to emerging rho kinase inhibitors that aim to augment neuroprotection.

Routing administration pathways further diversifies treatment strategies, with sustained-release implants, systemic formulations, and topical preparations each offering distinct advantages in efficacy and patient adherence. The product landscape balances branded innovations against high-quality generics, driving competitive pricing dynamics and influencing prescribing trends. Distribution channels extend from hospital pharmacies and retail outlets to online pharmacy platforms, while end-use environments span ambulatory surgery centers, ophthalmology clinics, hospitals, and homecare settings. This multifaceted segmentation analysis empowers decision makers to identify white spaces and align strategic investments with evolving clinical and commercial imperatives.

Mapping Regional Drivers and Challenges Across the Americas Europe Middle East and Africa Alongside Asia Pacific to Unlock Growth Potential in Glaucoma Care

Regional market dynamics exert a profound influence on glaucoma care strategies and investment priorities. In the Americas, robust healthcare infrastructure, favorable reimbursement frameworks, and a culture of early disease screening drive rapid adoption of novel therapeutics and surgical innovations, particularly in the United States and Canada. Transitioning to Europe, Middle East and Africa, regulatory harmonization across the European Union facilitates market entry for advanced devices, yet disparities in healthcare funding and access create pockets of unmet need, especially in emerging markets.

Meanwhile, Asia-Pacific emerges as a critical growth frontier, fueled by large patient populations in China and India, expanding ophthalmic specialist networks, and proactive government initiatives targeting age-related eye diseases. Within this diverse region, local manufacturers and strategic alliances are accelerating the development of cost-effective solutions tailored to specific patient demographics. Understanding these regional drivers and barriers is essential for stakeholders seeking to optimize market penetration, streamline supply chains, and harness the full potential of global glaucoma treatment opportunities.

Profiling Leading Innovators and Strategic Partnerships That Propel Competitive Dynamics in the Global Glaucoma Treatment Market

Analysis of leading industry players highlights a competitive landscape defined by innovation, strategic partnerships, and targeted acquisitions. Major pharmaceutical entities continue to expand their glaucoma portfolios through R&D investments in next-generation drug classes, while specialist device manufacturers focus on refining minimally invasive surgical platforms and next-wave sustained-release delivery systems. Collaborations between ophthalmology experts and engineering teams are accelerating product development timelines and enabling seamless integration of digital diagnostics with therapeutic solutions.

Meanwhile, emerging companies are leveraging niche expertise in areas such as biocompatible implant materials and neuroprotective agents to carve out specialized market positions. Cross-sector alliances between device innovators and software developers are further enhancing procedural accuracy, predictive analytics, and patient engagement tools. This evolving interplay among established multinationals, nimble startups, and cross-industry consortia is reshaping competitive dynamics and setting new benchmarks for clinical outcomes, commercial performance, and long-term value creation.

Implementing Concrete Strategic Recommendations to Leverage Disruptive Innovations and Optimize Stakeholder Outcomes in Glaucoma Care

Industry leaders must embrace concrete strategies to capitalize on emerging opportunities and fortify their market positions. Prioritizing investment in sustained-release delivery technologies and minimally invasive surgical solutions will address patient adherence challenges and streamline care pathways. Concurrently, strengthening supply chain resilience through geographic diversification and strategic sourcing agreements is paramount to mitigate potential tariff disruptions and raw material shortages.

In parallel, stakeholders should foster collaborative ecosystems that unite device manufacturers, pharmaceutical companies, healthcare providers, and payers under shared risk-and-reward frameworks. Integrating digital health platforms-ranging from remote monitoring applications to AI-enabled diagnostic support-can enhance patient outcomes while unlocking new revenue streams. Finally, tailoring market entry strategies to regional nuances, particularly in high-growth Asia-Pacific markets, will optimize resource allocation and accelerate adoption of breakthrough therapies. By executing these recommendations, organizations can align innovation with patient-centric value creation and secure sustainable competitive advantage.

Detailing Rigorous Multi-Phased Research Methodology Combining Primary Engagements and Secondary Intelligence for Unbiased Glaucoma Market Analysis

This research employs a multi-phased methodology designed to ensure comprehensive and unbiased market insights. The process began with exhaustive secondary research, including peer-reviewed publications, regulatory filings, patent databases, and corporate disclosures, to map industry developments, product pipelines, and regulatory landscapes. These qualitative findings informed the design of a primary research framework that encompassed in-depth interviews with ophthalmologists, glaucoma surgeons, hospital formulary managers, and distribution channel executives across key geographies.

Data triangulation techniques were applied to validate insights and reconcile discrepancies between primary and secondary sources. Quantitative analyses leveraged statistical modeling to assess historical trends and scenario planning, while qualitative thematic analysis provided context on emerging innovations and stakeholder perspectives. Through iterative validation with subject matter experts and iterative review cycles, the methodology delivers robust, actionable intelligence to support strategic decision making.

Synthesizing Key Findings and Conclusive Perspectives to Catalyze Informed Decision Making in Glaucoma Treatment Innovations

The synthesis of strategic insights underscores a pivotal moment in glaucoma treatment, marked by convergent innovations in drug delivery, surgical techniques, and digital diagnostics. The anticipated impact of 2025 tariff adjustments highlights the necessity for agile supply chain strategies and localized manufacturing capabilities to sustain access to critical therapies. Segmentation analysis reveals nuanced opportunities across treatment modalities, drug classes, administration routes, product types, distribution channels, and end-use settings, while regional assessments illuminate distinct growth drivers and barriers in the Americas, Europe Middle East and Africa, and Asia-Pacific.

Competitive profiling demonstrates that success will hinge on cross-industry collaborations, targeted investments in next-generation technologies, and value-based contracting models. By aligning recommendations with evolving clinical and commercial imperatives, stakeholders can navigate the complexities of the glaucoma market and deliver meaningful improvements in patient outcomes. This conclusion serves as a springboard for informed strategy development and underscores the importance of continuous innovation in combating this sight-threatening disease.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Treatment Type
    • Laser Treatment
      • Argon Laser Trabeculoplasty
      • Endocyclophotocoagulation
      • Selective Laser Trabeculoplasty
    • Medical Treatment
    • Surgical Treatment
      • Drainage Device Implantation
      • Minimally Invasive Glaucoma Surgery
        • Hydrus
        • IStent
        • Xen Gel Stent
      • Trabeculectomy
  • Drug Class
    • Alpha Agonists
    • Beta Blockers
    • Carbonic Anhydrase Inhibitors
    • Miotics
    • Prostaglandin Analogs
    • Rho Kinase Inhibitors
  • Route Of Administration
    • Sustained Release
    • Systemic
    • Topical
  • Product Type
    • Branded
    • Generic
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • End Use
    • Ambulatory Surgery Centers
    • Homecare
    • Hospitals
    • Ophthalmology Clinics
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • AbbVie Inc.
  • Novartis AG
  • Pfizer Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Merck & Co., Inc.
  • Bausch & Lomb Corporation
  • Sun Pharmaceutical Industries Ltd.
  • Aerie Pharmaceuticals, Inc.
  • Théa Pharma International SAS
  • Takeda Pharmaceutical Company Limited

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Adoption of sustained release drug delivery implants for long term intraocular pressure control
5.2. Integration of artificial intelligence imaging tools for early glaucoma detection and monitoring
5.3. Emergence of minimally invasive glaucoma surgery devices offering reduced risk and faster recovery
5.4. Development of novel rho kinase inhibitors aimed at improving ocular hypertension management efficacy
5.5. Expansion of teleophthalmology services enabling remote intraocular pressure monitoring and consultation
5.6. Strategic collaborations between pharmaceutical companies and biotech startups for gene therapy advances in glaucoma
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Glaucoma Treatment Market, by Treatment Type
8.1. Introduction
8.2. Laser Treatment
8.2.1. Argon Laser Trabeculoplasty
8.2.2. Endocyclophotocoagulation
8.2.3. Selective Laser Trabeculoplasty
8.3. Medical Treatment
8.4. Surgical Treatment
8.4.1. Drainage Device Implantation
8.4.2. Minimally Invasive Glaucoma Surgery
8.4.2.1. Hydrus
8.4.2.2. IStent
8.4.2.3. Xen Gel Stent
8.4.3. Trabeculectomy
9. Glaucoma Treatment Market, by Drug Class
9.1. Introduction
9.2. Alpha Agonists
9.3. Beta Blockers
9.4. Carbonic Anhydrase Inhibitors
9.5. Miotics
9.6. Prostaglandin Analogs
9.7. Rho Kinase Inhibitors
10. Glaucoma Treatment Market, by Route Of Administration
10.1. Introduction
10.2. Sustained Release
10.3. Systemic
10.4. Topical
11. Glaucoma Treatment Market, by Product Type
11.1. Introduction
11.2. Branded
11.3. Generic
12. Glaucoma Treatment Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.4. Retail Pharmacy
13. Glaucoma Treatment Market, by End Use
13.1. Introduction
13.2. Ambulatory Surgery Centers
13.3. Homecare
13.4. Hospitals
13.5. Ophthalmology Clinics
14. Americas Glaucoma Treatment Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Glaucoma Treatment Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Glaucoma Treatment Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. AbbVie Inc.
17.3.2. Novartis AG
17.3.3. Pfizer Inc.
17.3.4. Santen Pharmaceutical Co., Ltd.
17.3.5. Merck & Co., Inc.
17.3.6. Bausch & Lomb Corporation
17.3.7. Sun Pharmaceutical Industries Ltd.
17.3.8. Aerie Pharmaceuticals, Inc.
17.3.9. Théa Pharma International SAS
17.3.10. Takeda Pharmaceutical Company Limited
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. GLAUCOMA TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. GLAUCOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. GLAUCOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. GLAUCOMA TREATMENT MARKET: RESEARCHAI
FIGURE 28. GLAUCOMA TREATMENT MARKET: RESEARCHSTATISTICS
FIGURE 29. GLAUCOMA TREATMENT MARKET: RESEARCHCONTACTS
FIGURE 30. GLAUCOMA TREATMENT MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. GLAUCOMA TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY ARGON LASER TRABECULOPLASTY, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY ARGON LASER TRABECULOPLASTY, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY ENDOCYCLOPHOTOCOAGULATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY ENDOCYCLOPHOTOCOAGULATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY SELECTIVE LASER TRABECULOPLASTY, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY SELECTIVE LASER TRABECULOPLASTY, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY MEDICAL TREATMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY MEDICAL TREATMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY DRAINAGE DEVICE IMPLANTATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY DRAINAGE DEVICE IMPLANTATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY HYDRUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY HYDRUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY ISTENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY ISTENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY XEN GEL STENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY XEN GEL STENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY TRABECULECTOMY, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY TRABECULECTOMY, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY ALPHA AGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY ALPHA AGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY BETA BLOCKERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY BETA BLOCKERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY MIOTICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY MIOTICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY PROSTAGLANDIN ANALOGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY PROSTAGLANDIN ANALOGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY RHO KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY RHO KINASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY SUSTAINED RELEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY SUSTAINED RELEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY SYSTEMIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY SYSTEMIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY BRANDED, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY GENERIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY HOMECARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY HOMECARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 127. CANADA GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 128. CANADA GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 129. CANADA GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2018-2024 (USD MILLION)
TABLE 130. CANADA GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2025-2030 (USD MILLION)
TABLE 131. CANADA GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 132. CANADA GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 133. CANADA GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2018-2024 (USD MILLION)
TABLE 134. CANADA GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2025-2030 (USD MILLION)
TABLE 135. CANADA GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 136. CANADA GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 137. CANADA GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 138. CANADA GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 139. CANADA GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 140. CANADA GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 141. CANADA GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 142. CANADA GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 143. CANADA GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 144. CANADA GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 145. MEXICO GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 146. MEXICO GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 147. MEXICO GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2018-2024 (USD MILLION)
TABLE 148. MEXICO GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2025-2030 (USD MILLION)
TABLE 149. MEXICO GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 150. MEXICO GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 151. MEXICO GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2018-2024 (USD MILLION)
TABLE 152. MEXICO GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2025-2030 (USD MILLION)
TABLE 153. MEXICO GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 154. MEXICO GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 155. MEXICO GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 156. MEXICO GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 157. MEXICO GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 158. MEXICO GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 159. MEXICO GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 160. MEXICO GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 161. MEXICO GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 162. MEXICO GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 163. BRAZIL GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 164. BRAZIL GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 165. BRAZIL GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2018-2024 (USD MILLION)
TABLE 166. BRAZIL GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2025-2030 (USD MILLION)
TABLE 167. BRAZIL GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 168. BRAZIL GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 169. BRAZIL GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2018-2024 (USD MILLION)
TABLE 170. BRAZIL GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2025-2030 (USD MILLION)
TABLE 171. BRAZIL GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 172. BRAZIL GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 173. BRAZIL GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 174. BRAZIL GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 175. BRAZIL GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 176. BRAZIL GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 177. BRAZIL GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 178. BRAZIL GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 179. BRAZIL GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 180. BRAZIL GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 181. ARGENTINA GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 182. ARGENTINA GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 183. ARGENTINA GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2018-2024 (USD MILLION)
TABLE 184. ARGENTINA GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2025-2030 (USD MILLION)
TABLE 185. ARGENTINA GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 186. ARGENTINA GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 187. ARGENTINA GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2018-2024 (USD MILLION)
TABLE 188. ARGENTINA GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2025-2030 (USD MILLION)
TABLE 189. ARGENTINA GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 190. ARGENTINA GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 191. ARGENTINA GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 192. ARGENTINA GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 193. ARGENTINA GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 194. ARGENTINA GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 195. ARGENTINA GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 196. ARGENTINA GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 197. ARGENTINA GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 198. ARGENTINA GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2018-2024 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2025-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2018-2024 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2025-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 219. UNITED KINGDOM GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 220. UNITED KINGDOM GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 221. UNITED KINGDOM GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2018-2024 (USD MILLION)
TABLE 222. UNITED KINGDOM GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2025-2030 (USD MILLION)
TABLE 223. UNITED KINGDOM GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 224. UNITED KINGDOM GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 225. UNITED KINGDOM GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2018-2024 (USD MILLION)
TABLE 226. UNITED KINGDOM GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2025-2030 (USD MILLION)
TABLE 227. UNITED KINGDOM GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 228. UNITED KINGDOM GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 230. UNITED KINGDOM GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 232. UNITED KINGDOM GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 234. UNITED KINGDOM GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 236. UNITED KINGDOM GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 237. GERMANY GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 238. GERMANY GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 239. GERMANY GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2018-2024 (USD MILLION)
TABLE 240. GERMANY GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2025-2030 (USD MILLION)
TABLE 241. GERMANY GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 242. GERMANY GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 243. GERMANY GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2018-2024 (USD MILLION)
TABLE 244. GERMANY GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2025-2030 (USD MILLION)
TABLE 245. GERMANY GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 246. GERMANY GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 247. GERMANY GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 248. GERMANY GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 249. GERMANY GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 250. GERMANY GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 251. GERMANY GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 252. GERMANY GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 253. GERMANY GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 254. GERMANY GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 255. FRANCE GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 256. FRANCE GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 257. FRANCE GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2018-2024 (USD MILLION)
TABLE 258. FRANCE GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2025-2030 (USD MILLION)
TABLE 259. FRANCE GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 260. FRANCE GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 261. FRANCE GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2018-2024 (USD MILLION)
TABLE 262. FRANCE GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2025-2030 (USD MILLION)
TABLE 263. FRANCE GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 264. FRANCE GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 265. FRANCE GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 266. FRANCE GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 267. FRANCE GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 268. FRANCE GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 269. FRANCE GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 270. FRANCE GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 271. FRANCE GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 272. FRANCE GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 273. RUSSIA GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 274. RUSSIA GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 275. RUSSIA GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2018-2024 (USD MILLION)
TABLE 276. RUSSIA GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2025-2030 (USD MILLION)
TABLE 277. RUSSIA GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 278. RUSSIA GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 279. RUSSIA GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2018-2024 (USD MILLION)
TABLE 280. RUSSIA GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2025-2030 (USD MILLION)
TABLE 281. RUSSIA GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 282. RUSSIA GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 283. RUSSIA GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 284. RUSSIA GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 285. RUSSIA GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 286. RUSSIA GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 287. RUSSIA GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 288. RUSSIA GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 289. RUSSIA GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 290. RUSSIA GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 291. ITALY GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 292. ITALY GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 293. ITALY GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2018-2024 (USD MILLION)
TABLE 294. ITALY GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2025-2030 (USD MILLION)
TABLE 295. ITALY GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 296. ITALY GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 297. ITALY GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2018-2024 (USD MILLION)
TABLE 298. ITALY GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2025-2030 (USD MILLION)
TABLE 299. ITALY GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 300. ITALY GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 301. ITALY GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 302. ITALY GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 303. ITALY GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 304. ITALY GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 305. ITALY GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 306. ITALY GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 307. ITALY GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 308. ITALY GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 309. SPAIN GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 310. SPAIN GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 311. SPAIN GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2018-2024 (USD MILLION)
TABLE 312. SPAIN GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2025-2030 (USD MILLION)
TABLE 313. SPAIN GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2024 (USD MILLION)
TABLE 314. SPAIN GLAUCOMA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2025-2030 (USD MILLION)
TABLE 315. SPAIN GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2018-2024 (USD MILLION)
TABLE 316. SPAIN GLAUCOMA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, 2025-2030 (USD MILLION)
TABLE 317. SPAIN GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 318. SPAIN GLAUCOMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 319. SPAIN GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 320. SPAIN GLAUCOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 321. SPAIN GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 322. SPAIN GLAUCOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 323. SPAIN GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 324. SPAIN GLAUCOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 325. SPAIN GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 326. SPAIN GLAUCOMA TREATMENT MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 327. UNITED ARAB EMIRATES GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 328. UNITED ARAB EMIRATES GLAUCOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 329. UNITED ARAB EMIRATES GLAUCOMA TREATMENT MARKET SIZE, BY LASER TREATMENT, 2018-2024 (USD MILLION)
TABLE 330. UNITED

Samples

Loading
LOADING...

Companies Mentioned

  • AbbVie Inc.
  • Novartis AG
  • Pfizer Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Merck & Co., Inc.
  • Bausch & Lomb Corporation
  • Sun Pharmaceutical Industries Ltd.
  • Aerie Pharmaceuticals, Inc.
  • Théa Pharma International SAS
  • Takeda Pharmaceutical Company Limited

Table Information

Report AttributeDetails
No. of Pages191
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 7.99 Billion
Forecasted Market Value ( USD ) by 2030 $ 12.28 Billion
Compound Annual Growth Rate9.0%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Glaucoma Therapeutics Market Size and Share - Outlook Report, Forecast Trends and Growth Analysis (2025-2034) - Product Image

Glaucoma Therapeutics Market Size and Share - Outlook Report, Forecast Trends and Growth Analysis (2025-2034)

  • Report
  • 400 Pages
  • Global
From
Glaucoma Treatment Market By Disease Type, By Treatment, By End User, Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 - 2035 - Product Image

Glaucoma Treatment Market By Disease Type, By Treatment, By End User, Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 - 2035

  • Report
  • 210 Pages
  • Global
From
Glaucoma Therapeutics - Global Strategic Business Report - Product Image

Glaucoma Therapeutics - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
Glaucoma - Pipeline Insight, 2025 - Product Image

Glaucoma - Pipeline Insight, 2025

  • Clinical Trials
  • 170 Pages
  • Global
From
Uveitic Glaucoma - Pipeline Insight, 2025 - Product Image

Uveitic Glaucoma - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From

About the Glaucoma Drug Market

The Glaucoma Drug market is a subset of the Optical Disorders Drugs market, which includes medications used to treat a variety of eye conditions. Glaucoma is a group of eye diseases that cause damage to the optic nerve, resulting in vision loss. Glaucoma drugs are used to reduce intraocular pressure, which is the main risk factor for glaucoma. These drugs can be administered orally, topically, or through injections. Commonly used glaucoma drugs include prostaglandin analogs, beta blockers, alpha agonists, carbonic anhydrase inhibitors, and cholinergic agonists. Some of the major companies in the Glaucoma Drug market include Allergan, Pfizer, Merck, Novartis, Bausch Health, Sun Pharmaceuticals, Santen Pharmaceuticals, and Alcon. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.